Moodley Keymanthri, Kleinsmidt Anita
Dev World Bioeth. 2021 Sep;21(3):125-130. doi: 10.1111/dewb.12277. Epub 2020 Aug 7.
Concerns have been raised around the alleged commercialisation of South African genetic material by various research institutes nationally and abroad. We consider whether the Protection of Personal Information Act in South Africa will conflict with or complement existing protections in health law and research ethics. The Act is not applicable to de-identified samples that cannot be re-identified but we question whether genetic samples can ever be truly de-identified. The research participants in this matter provided consent for use of their samples for research but did not consent to commercialisation by global research institutions, and neither did the researchers. We suggest that consent models incorporating broad consent as an option should include explicit discussions around benefit sharing and commercialisation. Mistrust between researchers and participants impedes scientific research and can harm relationships built up over the years between South African researchers and local communities.
国内外各研究机构对南非遗传物质的所谓商业化问题表示了担忧。我们探讨南非的《个人信息保护法》是否会与卫生法和研究伦理中的现有保护措施产生冲突或互补。该法案不适用于无法重新识别身份的匿名样本,但我们质疑基因样本是否真的能做到完全匿名。此事中的研究参与者同意将其样本用于研究,但不同意全球研究机构将其商业化,研究人员也不同意。我们建议,将广泛同意作为一种选项的同意模式应包括围绕利益分享和商业化的明确讨论。研究人员与参与者之间的不信任阻碍了科学研究,可能会损害南非研究人员与当地社区多年来建立的关系。